Cite Filings / NRIX / 0001493152-25-006846
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13G

Statement of Beneficial Ownership

Nurix Therapeutics, Inc. · Filed 2025-02-14 · Acc 0001493152-25-006846

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

  • 2026-05-06 SCHEDULE 13G Statement of Beneficial Ownership
  • 2025-02-14 SCHEDULE 13G Statement of Beneficial Ownership
  • 2025-02-14 SCHEDULE 13G Statement of Beneficial Ownership
  • 2025-02-14 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-02-13 4 Options or other derivatives
  • 2025-02-13 4 Options or other derivatives
  • 2025-02-13 4 Options or other derivatives

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · Perceptive Advisors LLC 4.9%
  2. 2026-11-16 SCHEDULE 13G/A · Deep Track Capital, LP 5.49%
  3. 2026-11-16 SCHEDULE 13G/A · Rubric Capital Management LP 4.55%
  4. 2026-11-16 SCHEDULE 13G/A · Vestal Point Capital, LP 6.4%
  5. 2026-11-16 SCHEDULE 13G/A · T. Rowe Price Associates, Inc. 4.4%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…